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Introduction
Metastatic  Ewing’s  sarcoma  of  the  pelvis  has  an
extremely  poor  prognosis  in  adult  patients.1 We
report the case of a woman aged 32 years at diag-
nosis, who developed skeletal metastases within 20
months of diagnosis but following treatment remains
disease-free at 10 years.
Case report
A 32-year-old woman was referred to Weston Park
Hospital in 1990 with a Ewing’s sarcoma of the right
superior pubic ramus  (Fig. 1a,b). Following  three
cycles of pre-operative chemotherapy with ifosfamide
vincristine and doxorubicin (IVAD),she underwent a
two-stage tumour excision and endoprosthesis with a
titanium hemipelvic replacement. She then received
post-operative chemotherapy with the same agents,
substituting actinomycin D for doxorubicin after a
total of six cycles of IVAD during which time her
renal function deteriorated (Table 1). Her endopros-
thetic  surgery  was  complicated  by  a  streptococcal
wound  infection  and  subsequently  dislocation  of 
her prosthesis.
Eight  months after  completion of  chemotherapy
(20 months after surgery), she experienced discom-
fort  in  the  chest, and a  chest  radiograph  revealed
multiple  lytic  metastases  in  the  ribs  (Fig. 2). CT
scanning demonstrated no soft  tissue extension of
these  lesions. A  99-technetium  isotope  bone  scan
revealed areas of increased uptake in the pelvis, ribs,
spine and sternum, consistent with multiple metas-
tases (Fig. 3, left). Her full blood count was normal.
Given  the  typical  appearances  of  metastases  both
radiologically and on isotope bone scanning, con￿ r-
matory biopsy was not performed. She was subse-
quently treated with ￿ ve cycles of carboplatin and
methotrexate. A further cycle of chemotherapy was
not  given  because  of  deterioration  in  her  renal 
function  as  assessed  by  both  creatinine  clearance
(Table 1) and by an increase in creatinine from 90
m mol/l (pre-chemotherapy) to 250 m mol/l.The chest
pain persisted and required radiotherapy (single frac-
tion of 600cGy) to the left lateral ribs and the left hip
(2000 cGy in ￿ ve fractions). In addition, three cycles
of intravenous pamidronate (120 mg per cycle) were
also given for the bone pain, with good, but tempo-
rary, symptomatic relief.
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Abstract
Patient:We report a 32-year-old women with a pelvic Ewing’s sarcoma, who developed skeletal metastases within 20 months
of diagnosis but following treatment remains disease-free at 10 years.
Discussion: Ewing’s sarcoma is a highly malignant tumour of bone. Presentation of a pelvic tumour over the age of 30 years
is extremely rare and associated with a poor prognosis. Early recurrence is also associated with an extremely grave prog-
nosis. In our patient there was little or no response to salvage chemotherapy, but, against the odds, remission was induced
with pamidronate and palliative radiotherapy to some but not all sites of disease.This remission has been maintained without
additional therapy for a further 5 years.
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DOI: 10.1080/1357714021000022140Six  months  later  (late  1992), a  further  6-week
course of low-dose weekly palliative  chemotherapy
with  vincristine, epirubicin and  cyclophosphamide
was administered.This did not produce any signi￿ -
cant symptomatic improvement and was followed by
palliative radiotherapy to the left shoulder (800 cGy
in a single fraction) and again to the left hip (800 cGy
in  a  single  fraction). Intermittent  infusions  of
pamidronate 120 mg were continued every 4 to 12
weeks as required for pain with good symptomatic
improvement.A further course of fractionated radio-
therapy (1250 cGy in ￿ ve fractions) for a recurrence
of severe bone pain in her lower ribs was required in
late 1993.Isotope bone scanning at this stage demon-
strated further increased uptake in the pubic rami
and persistence of the other skeletal lesions.
In  1994, she  suffered  insuf￿ ciency  fractures  of
both left pubic rami and underwent investigations of
bone metabolism. These revealed normal calcium,
vitamin  D  and  parathyroid  hormone  but  grossly
elevated hydroxyproline and pyridinoline. A unicor-
tical, double-labelled iliac crest bone biopsy revealed
renal  osteodystrophy  with  signs  of  hyperparathy-
roidism and no evidence of osteomalacia.Treatment
with  calcitriol  corrected  her  abnormal  bone
biochemistry. Isotope  bone  scanning  at  that  stage
(1995) revealed no evidence of skeletal metastases,
and the focal increased uptake in the ribs had disap-
peared (Fig. 3, right).
Since 1995, the patient has remained in remission
with  a  recent assessment revealing  no evidence of
metastatic disease. Serial isotope bone scans remain
unchanged from 1995.
Discussion
Ewing’s  sarcoma  is  a  highly  malignant  round-cell
tumour of bone that occurs most commonly between
the ages of 10 and 25 years.Presentation over the age
of 30 years, as in our patient, is extremely rare and is
associated with a poor prognosis.1 The pelvis is the
most commonly affected site2 and carries an espe-
cially poor prognosis with high  rates of both local
recurrence and distant metastases.1–4 Surgical resec-
tion in combination with chemotherapy has improved
the prognosis of pelvic Ewing’s sarcoma,1–4 but the
outlook remains poor in those patients who develop
skeletal metastases.Of the seven patients over the age
of 20 years managed at UCLA,3 who developed bone
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Table 1. Creatinine clearance in this patient over time
Date Notes Creatinine clearance (ml/min)
1990 Pre-chemotherapy 90
January 1991 Post IVAD 70
December 1991 After recurrence 50
Late 1992 After salvage chemotherapy 30
All subsequent measurements 30–35
Fig. 1. (a) Radiograph of the pelvis demonstrating a tumour of the right superior pubic ramus. (b) Histology (H&E) characteristic
of Ewing’s sarcoma.
Fig. 2. Radiograph of ribs demonstrating destructive osteolytic
lesions affecting ribs 3 and 4.metastases, the median survival from date of primary
diagnosis  was  21  months  (range  6–56  months).
Similarly,in two patients of the same age group in the
Mayo Clinic,4 death occurred within a year of diag-
nosis. Early recurrence can therefore be seen to be
associated with an extremely grave prognosis.
This patient had widespread lytic skeletal metas-
tases, which developed within 2 years of the primary
tumour, treated by a combination of chemotherapy,
radiotherapy and bisphosphonates.There was little or
no response to salvage chemotherapy,but,against the
odds, remission was induced with pamidronate and
palliative  radiotherapy to some but not all sites of
disease.This remission has been maintained without
additional therapy for a further 5 years. It is unlikely
that  radiotherapy  played  a  major  role  against  the
disease given the disseminated nature of the skeletal
changes on isotope bone scanning. It may, however,
be that salvage chemotherapy in 1991 and 1992 was
more effective than we estimated.What goes against
this  is  that  prolonged  survival  with  salvage
chemotherapy  in  metastatic  Ewing’s  disease  is
extremely rare.
The major determinant of a lack of response in this
case is persisting pain and poor mobility. However,
follow-up X-rays failed to demonstrate healing of the
bone  lesions  during  chemotherapy. Additionally,
bone scanning only began to show fading of the hot
spots from 1995.
Bisphosphonates  have  potent  effects  on  bone
metabolism  and  the  bone  marrow  microenviron-
ment. There are also in vitro data that suggest that
high concentrations of bisphosphonates may inhibit
tumour cell proliferation and promote apoptosis of
tumour cells.5 Whether this remarkable response is
related  to  these  phenomena  is  impossible  to
conclude, but the possibility is intriguing and further
in  vivo  evaluation  of  the  ‘antitumour  effects’ of
bisphosphonates is required.
This is a complex case and no one intervention is
responsible for the prolonged survival in this patient.
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Fig. 3. 99-Tc isotope bone scans.(Left) pre-therapy with multiple metastases and (right) post-therapy with resolution and remission
induced.